International survey of patients undergoing percutaneous coronary intervention and their attitudes toward pharmacogenetic testing

Objective To evaluate perceptions toward pharmacogenetic testing of patients undergoing percutaneous coronary intervention (PCI) who are prescribed dual antiplatelet therapy (DAPT) and whether geographical differences in these perceptions exist. Participants and methods TAILOR-PCI is the largest genotype-based cardiovascular clinical trial randomizing participants to conventional DAPT or prospective genotyping-guided DAPT. Enrolled patients completed surveys before and 6 months after randomization. Results A total of 1327 patients completed baseline surveys of whom 28, 29, and 43% were from Korea, Canada and the USA, respectively. Most patients (77%) valued identifying pharmacogenetic variants; however, fewer Koreans (44%) as compared with Canadians (91%) and USA (89%) patients identified pharmacogenetics as being important (P<0.001). After adjusting for age, sex, and country, those who were confident in their ability to understand genetic information were significantly more likely to value identifying pharmacogenetic variants (odds ratio: 30.0; 95% confidence interval: 20.5–43.8). Only 21% of Koreans, as opposed to 86 and 77% of patients in Canada and USA, respectively, were confident in their ability to understand genetic information (P<0.001). Conclusion Although genetically mediated clopidogrel resistance is more prevalent amongst Asians, Koreans undergoing PCI identified pharmacogenetic variants as less important to their healthcare, likely related to their lack of confidence in their ability to understand genetic information. To enable successful implementation of pharmacogenetic testing on a global scale, the possibility of international population differences in perceptions should be considered.

[1]  Iyn-Hyang Lee,et al.  Awareness and attitude of the public toward personalized medicine in Korea , 2018, PloS one.

[2]  Joshua C Denny,et al.  Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. , 2018, JACC. Cardiovascular interventions.

[3]  Jeffrey L. Anderson,et al.  Effect of Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty: The GIFT Randomized Clinical Trial , 2017, JAMA.

[4]  Brittany A. Borden,et al.  Patient Perceptions of Care as Influenced by a Large Institutional Pharmacogenomic Implementation Program , 2017, Clinical pharmacology and therapeutics.

[5]  M. Subramaniam,et al.  Clinicians' perceptions of pharmacogenomics use in psychiatry. , 2017, Pharmacogenomics.

[6]  Carolyn R Rohrer Vitek,et al.  Participant perceived understanding and perspectives toward pharmacogenomics: Mayo Clinic Right Drug, Right Dose, Right Time (RIGHT) Protocol , 2016, Genetics in Medicine.

[7]  J. Wardle,et al.  Genetic testing and personalized ovarian cancer screening: a survey of public attitudes , 2016, BMC Women's Health.

[8]  D. Sargent,et al.  Genotype-based clinical trials in cardiovascular disease , 2015, Nature Reviews Cardiology.

[9]  A. Stewart,et al.  Clinical Implementation of Cardiovascular Pharmacogenomics. , 2015, Mayo Clinic proceedings.

[10]  Maurizio Fava,et al.  Pharmacogenetic-guided psychiatric intervention associated with increased adherence and cost savings. , 2014, The American journal of managed care.

[11]  M. McGuire,et al.  Risk Management and Healthcare Policy Dovepress Adherence and Health Care Costs , 2022 .

[12]  Beth A. Glenn,et al.  Barriers to genetic testing for breast cancer risk among ethnic minority women: an exploratory study. , 2012, Ethnicity & disease.

[13]  Julianne M. O’Daniel,et al.  Survey of U.S. Public Attitudes Towards Pharmacogenetic Testing , 2011, The Pharmacogenomics Journal.

[14]  Y. Jang,et al.  Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents , 2011, Heart.

[15]  D. Roter,et al.  Patient reactions to personalized medicine vignettes: An experimental design , 2011, Genetics in Medicine.

[16]  J. Ferrières,et al.  Genetic determinants of response to clopidogrel and cardiovascular events. , 2009, The New England journal of medicine.

[17]  Jaekyu Shin,et al.  Survey on warfarin pharmacogenetic testing among anticoagulation providers. , 2009, Pharmacogenomics.

[18]  R. Weinshilboum,et al.  Cardiovascular pharmacogenomics and individualized drug therapy , 2009, Nature Reviews Cardiology.

[19]  Claes Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.

[20]  E. Antman,et al.  Cytochrome p-450 polymorphisms and response to clopidogrel. , 2009, The New England journal of medicine.

[21]  A. Issa,et al.  Assessing Patient Readiness for the Clinical Adoption of Personalized Medicine , 2009, Public Health Genomics.

[22]  J. Jankovic,et al.  Comparing knowledge and attitudes towards genetic testing in Parkinson's disease in an American and Asian population , 2007, Journal of the Neurological Sciences.

[23]  J. Brockmöller,et al.  Patients' and physicians' perspectives on pharmacogenetic testing. , 2006, Pharmacogenomics.

[24]  I. Björnsdottir,et al.  A lay prescription for tailor-made drugs--focus group reflections on pharmacogenomics. , 2005, Health policy.

[25]  Jane Wardle,et al.  Public interest in genetic testing for susceptibility to heart disease and cancer: a population-based survey in the UK. , 2004, Preventive medicine.

[26]  A. Aro,et al.  Does Knowledge Make a Difference? The Association Between Knowledge About Genes and Attitudes Toward Gene Tests , 2000, Journal of health communication.